José M de la Torre Hernández1, José R Rumoroso2, Soledad Ojeda3, Salvatore Brugaletta4, José D Cascón5, Cristina Ruisánchez6, Joaquín Sánchez Gila7, Jessica Roa8, Helena Tizón9, Hipólito Gutiérrez10, Mariano Larman11, Tamara García Camarero6, Eduardo Pinar12, José F Díaz8, Manuel Pan3, Miren Morillas Bueno2, José M Oyonarte7, Luis Ruiz Guerrero6, Mireia Ble9, Ramón Rubio Patón5, Román Arnold10, Kattalin Echegaray11, Gonzalo de la Morena12, Manel Sabate4. 1. Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain. Electronic address: he1thj@humv.es. 2. Servicio de Cardiología, Hospital de Galdácano, Galdácano, Vizcaya, Spain. 3. Servicio de Cardiología, Hospital Reina Sofía, Córdoba, Spain. 4. Servicio de Cardiología, Hospital Clinic, Barcelona, Spain. 5. Servicio de Cardiología, Hospital de Cartagena, Cartagena, Murcia, Spain. 6. Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain. 7. Servicio de Cardiología, Hospital Virgen de las Nieves, Granada, Spain. 8. Servicio de Cardiología, Hospital Juan Ramón Jiménez, Huelva, Spain. 9. Grupo de Investigación Biomédica en Enfermedades del Corazón, Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Hospital del Mar, Barcelona, Spain. 10. Servicio de Cardiología, Hospital Clínico de Valladolid, Valladolid, Spain. 11. Servicio de Cardiología, Hospital Donostia, San Sebastián, Guipúzcoa, Spain. 12. Servicio de Cardiología, Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Abstract
INTRODUCTION AND OBJECTIVES: Bioresorbable vascular scaffolds (BVS) have the potential to restore vasomotion but the clinical implications are unknown. We sought to evaluate angina and ischemia in the long-term in patients treated with BVS and metallic drug-eluting stents (mDES). METHODS: Multicenter study including patients with 24 ± 6 months of uneventful follow-up, in which stress echocardiography was performed and functional status was assessed by the Seattle Angina Questionnaire (SAQ). The primary endpoint was a positive result in stress echocardiography. RESULTS: The study included 102 patients treated with BVS and 106 with mDES. There were no differences in the patients' baseline characteristics. Recurrent angina was found in 18 patients (17.6%) in the BVS group vs 25 (23.5%) in the mDES group (P = .37), but SAQ results were significantly better in the BVS group (angina frequency 96.0 ± 8.0 vs 89.2 ± 29.7; P = .02). Stress echocardiography was positive in 11/92 (11.9%) of BVS patients vs 9/96 (9.4%) of mDES patients in the (P = .71) and angina was induced in 2/102 (1.9%) vs 7/106 (6.6%) (P = .18), respectively, but exercise performance was better in the BVS group even in those with positive tests (exercise duration 9.0 ± 2.0minutes vs 7.7 ± 1.8minutes; P = .02). A propensity score matching analysis yielded similar results. CONCLUSIONS: The primary endpoint was similar in both groups. In addition, recurrent angina was similar in patients with BVS and mDES. The better functional status, assessed by means of SAQ and exercise performance, detected in patients receiving BVS should be confirmed in further studies.
INTRODUCTION AND OBJECTIVES: Bioresorbable vascular scaffolds (BVS) have the potential to restore vasomotion but the clinical implications are unknown. We sought to evaluate angina and ischemia in the long-term in patients treated with BVS and metallic drug-eluting stents (mDES). METHODS: Multicenter study including patients with 24 ± 6 months of uneventful follow-up, in which stress echocardiography was performed and functional status was assessed by the Seattle Angina Questionnaire (SAQ). The primary endpoint was a positive result in stress echocardiography. RESULTS: The study included 102 patients treated with BVS and 106 with mDES. There were no differences in the patients' baseline characteristics. Recurrent angina was found in 18 patients (17.6%) in the BVS group vs 25 (23.5%) in the mDES group (P = .37), but SAQ results were significantly better in the BVS group (angina frequency 96.0 ± 8.0 vs 89.2 ± 29.7; P = .02). Stress echocardiography was positive in 11/92 (11.9%) of BVS patients vs 9/96 (9.4%) of mDESpatients in the (P = .71) and angina was induced in 2/102 (1.9%) vs 7/106 (6.6%) (P = .18), respectively, but exercise performance was better in the BVS group even in those with positive tests (exercise duration 9.0 ± 2.0minutes vs 7.7 ± 1.8minutes; P = .02). A propensity score matching analysis yielded similar results. CONCLUSIONS: The primary endpoint was similar in both groups. In addition, recurrent angina was similar in patients with BVS and mDES. The better functional status, assessed by means of SAQ and exercise performance, detected in patients receiving BVS should be confirmed in further studies.
Authors: Kathrin Pahmeier; Silke Neusser; Christian Hamm; Johannes Kastner; Jochen Wöhrle; Ralf Zahn; Stephan Achenbach; Julinda Mehilli; Tommaso Gori; Christoph Naber; Holger Nef; Till Neumann; Gert Richardt; Axel Schmermund; Christoph Claas; Thomas Riemer; Janine Biermann-Stallwitz Journal: BMC Cardiovasc Disord Date: 2022-08-20 Impact factor: 2.174